[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20191650A1 - Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Info

Publication number
PE20191650A1
PE20191650A1 PE2019001933A PE2019001933A PE20191650A1 PE 20191650 A1 PE20191650 A1 PE 20191650A1 PE 2019001933 A PE2019001933 A PE 2019001933A PE 2019001933 A PE2019001933 A PE 2019001933A PE 20191650 A1 PE20191650 A1 PE 20191650A1
Authority
PE
Peru
Prior art keywords
indoline derivatives
inhibitors
viral replication
compounds
derivatives substituted
Prior art date
Application number
PE2019001933A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-Franã§Ois Bonfanti
Erwin Coesemans
Pierre Jean-Marie Bernard Raboisson
Arnaud Didier M Marchand
Dorothee Alice Marie-Eve Bardiot
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of PE20191650A1 publication Critical patent/PE20191650A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a un compuesto de formula I, donde R1 es Cl o F; R2 es -CH2CH2-OH o C3-5alquilCOOH; R3 es trifluorometilo, o trifluorometoxi; R4 es H, F o metoxi; y R5 es H o metilo; una sal, solvato, o polimorfo farmaceuticamente aceptable. Estos compuestos son derivados de indolina sustituidos e inhiben la replicacion virica de dengue. Tambien se refiere a procesos para preparar dichos compuestos, compuestos intermedios, una composicion farmaceutica que comprende dicho compuesto, un segundo principio activo o mas, y excipientes; en donde el segundo principio activo es un agente anti-virico; tambien se refiere a su uso en el tratamiento de la infeccion del dengue y para prevenir o tratar enfermedades asociadas a la infeccion del dengue.
PE2019001933A 2017-03-31 2018-03-29 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue PE20191650A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164048 2017-03-31
PCT/EP2018/058079 WO2018178240A1 (en) 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
PE20191650A1 true PE20191650A1 (es) 2019-11-07

Family

ID=58464340

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001933A PE20191650A1 (es) 2017-03-31 2018-03-29 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Country Status (32)

Country Link
US (1) US11083707B2 (es)
EP (1) EP3601266B1 (es)
JP (1) JP7203752B2 (es)
KR (1) KR102530832B1 (es)
CN (1) CN110461831B (es)
AR (1) AR111314A1 (es)
AU (1) AU2018246301B2 (es)
BR (1) BR112019020175A2 (es)
CA (1) CA3055867C (es)
CL (1) CL2019002745A1 (es)
CO (1) CO2019010295A2 (es)
CR (1) CR20190446A (es)
DK (1) DK3601266T3 (es)
EA (1) EA039784B1 (es)
EC (1) ECSP19070369A (es)
ES (1) ES2884151T3 (es)
HR (1) HRP20210942T1 (es)
HU (1) HUE054678T2 (es)
IL (1) IL269658B (es)
JO (1) JOP20180025B1 (es)
LT (1) LT3601266T (es)
MX (1) MX2019011606A (es)
NI (1) NI201900099A (es)
PE (1) PE20191650A1 (es)
PH (1) PH12019502201A1 (es)
SG (1) SG11201908786VA (es)
SI (1) SI3601266T1 (es)
TW (1) TWI795393B (es)
UA (1) UA126288C2 (es)
UY (1) UY37645A (es)
WO (1) WO2018178240A1 (es)
ZA (1) ZA201906395B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190530A (es) 2017-05-22 2020-01-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
KR102625991B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
CN109485596A (zh) * 2018-12-19 2019-03-19 山东理工职业学院 一种含吲哚啉的登革病毒抑制剂的制备方法
CN112159325B (zh) * 2020-10-10 2022-11-25 浙江工业大学 一种合成2-氨基-3-硝基甲苯的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (en) 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20080262005A1 (en) * 2004-05-14 2008-10-23 Neurocrine Biosciences, Inc. Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto
KR20070098914A (ko) 2005-01-14 2007-10-05 제네랩스 테크놀로지스, 인코포레이티드 바이러스 감염을 치료하기 위한 인돌 유도체
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
JP2011522054A (ja) 2008-06-03 2011-07-28 シガ・テクノロジーズ・インコーポレーテッド デングウイルス感染の処置または予防のための小分子インヒビター
WO2010021878A1 (en) 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
SG182478A1 (en) 2010-01-15 2012-08-30 Gilead Sciences Inc Inhibitors of flaviviridae viruses
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
DK3099687T3 (en) 2014-01-31 2018-10-22 Bristol Myers Squibb Co MACROCYCLES WITH HETEROCYCLIC P2 'GROUPS AS FACTOR XIA INHIBITORS
KR102478311B1 (ko) 2014-10-01 2022-12-15 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 1치환 또는 2치환 인돌 유도체
KR102478309B1 (ko) 2014-10-01 2022-12-15 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 1치환 또는 2치환 인돌
NO2721243T3 (es) 2014-10-01 2018-10-20
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108601723B (zh) 2015-11-03 2022-05-17 硕腾服务有限责任公司 溶胶-凝胶聚合物复合材料及其用途
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
NZ746554A (en) 2016-04-01 2023-03-31 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
UA128326C2 (uk) 2016-04-01 2024-06-12 Амджен Інк. Химерний рецептор до flt3 та спосіб його застосування
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3436079T1 (sl) 2016-04-01 2022-01-31 Kite Pharma, Inc. Himerni antigen in T celični receptorji ter način uporabe
PL3436030T3 (pl) 2016-04-01 2022-12-19 Kite Pharma, Inc. Receptory chimeryczne i sposoby ich zastosowania
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190530A (es) 2017-05-22 2020-01-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
KR102625991B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체

Also Published As

Publication number Publication date
LT3601266T (lt) 2021-07-12
EA201992329A1 (ru) 2020-02-20
CO2019010295A2 (es) 2019-10-09
JP7203752B2 (ja) 2023-01-13
NI201900099A (es) 2020-03-11
CA3055867C (en) 2024-01-02
JOP20180025A1 (ar) 2019-01-30
ECSP19070369A (es) 2019-10-31
IL269658B (en) 2022-01-01
EA039784B1 (ru) 2022-03-14
AU2018246301A1 (en) 2019-09-19
HUE054678T2 (hu) 2021-09-28
KR20190137108A (ko) 2019-12-10
US11083707B2 (en) 2021-08-10
SG11201908786VA (en) 2019-10-30
US20200121647A1 (en) 2020-04-23
SI3601266T1 (sl) 2021-08-31
HRP20210942T1 (hr) 2021-10-15
WO2018178240A1 (en) 2018-10-04
ES2884151T3 (es) 2021-12-10
TWI795393B (zh) 2023-03-11
AU2018246301B2 (en) 2021-08-19
IL269658A (en) 2019-11-28
CN110461831A (zh) 2019-11-15
UA126288C2 (uk) 2022-09-14
JP2020512355A (ja) 2020-04-23
MX2019011606A (es) 2019-11-08
DK3601266T3 (da) 2021-07-19
CN110461831B (zh) 2022-11-01
JOP20180025B1 (ar) 2021-08-17
EP3601266B1 (en) 2021-04-28
ZA201906395B (en) 2021-05-26
KR102530832B1 (ko) 2023-05-09
PH12019502201A1 (en) 2020-09-28
EP3601266A1 (en) 2020-02-05
TW201900635A (zh) 2019-01-01
CL2019002745A1 (es) 2019-12-27
CR20190446A (es) 2019-11-29
BR112019020175A2 (pt) 2020-06-02
UY37645A (es) 2018-09-28
CA3055867A1 (en) 2018-10-04
AR111314A1 (es) 2019-06-26

Similar Documents

Publication Publication Date Title
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
UY36904A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY36903A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR120158A2 (es) Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии
AR102135A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue